LECT2 and metabolic dysfunction-associated steatohepatitis: It has been reported that Leukocyte cell-derived chemotaxin 2 (LECT2) is involved in immune reactions (Jung et al., 2018; Lu et al., 2020), severe liver injury (Segawa et al., 2001; Okumura et al., 2017; Slowik et al., 2019), cancer (L'Hermitte et al., 2019), nonalcoholic steatohepatitis (NASH) (Takata et al., 2021), nonalcoholic fatty liver disease (NAFLD) (Yoo et al., 2017) and so on.